Catalyst Pharmaceuticals Stock Forecast for 2023 - 2025 - 2030

Updated on 02/05/2023

Stock Rating
16
Price Target
$12.00
Consensus
Outperform
Downside
-25.47%
Analysts
0
Stock Rating
16
Downside
-25.47%
Analysts
0
Price Target
$12.00

Catalyst Pharmaceuticals Stock Forecast and Price Target

If Catalyst Pharmaceuticals's stock price reached the average yearlong target of $12.00 given by well-known analysts in recent months, there would be a potential downside of approximately -25.47% from its last closing price in February, 2023. This potential increase is based on a high estimate of $15.00 and a low estimate of $9.00.

$12.00

-25.47% Downside

Outperform
Outperform

Catalyst Pharmaceuticals Fair Value Forecast for 2023 - 2025 - 2030

In the last two years, Catalyst Pharmaceuticals's Price has grown by 23.33%, rising from $3.13 to $3.86. In the following year, 0 experts forecast that Catalyst Pharmaceuticals's Fair Value will decrease by 2.93%, to $3.75. In 2030, professionals predict that Catalyst Pharmaceuticals's Fair Value will decrease by 2.48%, to $3.76.

2022 Fair Value Forecast
$3.75
2023 Fair Value Forecast
$3.57
2024 Fair Value Forecast
$3.76
2025 Fair Value Forecast
$3.80
2026 Fair Value Forecast
$3.78
2027 Fair Value Forecast
$3.71
2028 Fair Value Forecast
$3.73
2029 Fair Value Forecast
$3.75
2030 Fair Value Forecast
$3.76

Catalyst Pharmaceuticals Revenue Forecast for 2023 - 2025 - 2030

In the last two years, Catalyst Pharmaceuticals's Revenue has grown by 37.65%, rising from $102.31M to $140.83M. In the following year, 0 experts forecast that Catalyst Pharmaceuticals's Revenue will decrease by 14.99%, to $119.71M. In 2030, professionals predict that Catalyst Pharmaceuticals's Revenue will decrease by 13.31%, to $122.08M.

2022 Rev Forecast
$0.12B
2023 Rev Forecast
$0.11B
2024 Rev Forecast
$0.12B
2025 Rev Forecast
$0.13B
2026 Rev Forecast
$0.12B
2027 Rev Forecast
$0.12B
2028 Rev Forecast
$0.12B
2029 Rev Forecast
$0.12B
2030 Rev Forecast
$0.12B

Catalyst Pharmaceuticals Dividend per Share Forecast for 2023 - 2025 - 2030

Catalyst Pharmaceuticals Free Cash Flow Forecast for 2023 - 2025 - 2030

Catalyst Pharmaceuticals's Free Cash Flow has seen impressive growth In the last two years, rising from $34.59M to $59.35M – a growth of 71.58%. In the following year, the 0 analysts surveyed believe that Catalyst Pharmaceuticals's Free Cash Flow will decrease by 23.82%, reaching $45.21M. According to professionals, by 2030, Catalyst Pharmaceuticals's Free Cash Flow will have decreased by 20.10%, falling down to $47.42M.

2022 FCF Forecast
$0.05B
2023 FCF Forecast
$0.04B
2024 FCF Forecast
$0.04B
2025 FCF Forecast
$0.05B
2026 FCF Forecast
$0.05B
2027 FCF Forecast
$0.05B
2028 FCF Forecast
$0.05B
2029 FCF Forecast
$0.05B
2030 FCF Forecast
$0.05B

Catalyst Pharmaceuticals Net Income Forecast for 2023 - 2025 - 2030

Catalyst Pharmaceuticals's Net Income has grown In the last two years, rising from $31.88M to $39.48M – a growth of 23.84%. In the next year, analysts believe that Net Income will reach $55.58M – an increase of 40.79%. For the next nine years, experts predict that Catalyst Pharmaceuticals's Net Income will grow at a rate of 48.65%.

2022 NI Forecast
$0.06B
2023 NI Forecast
$0.06B
2024 NI Forecast
$0.07B
2025 NI Forecast
$0.06B
2026 NI Forecast
$0.06B
2027 NI Forecast
$0.06B
2028 NI Forecast
$0.06B
2029 NI Forecast
$0.06B
2030 NI Forecast
$0.06B

Catalyst Pharmaceuticals EBITDA Forecast for 2023 - 2025 - 2030

In the last two years, Catalyst Pharmaceuticals's EBITDA has grown by 64.93%, rising from $31.88M to $52.58M. The next year, 0 experts forecast that Catalyst Pharmaceuticals's EBITDA will decrease by 21.84%, reaching $41.10M. In 2030, professionals predict that Catalyst Pharmaceuticals's EBITDA will decrease by 18.64%, reaching $42.78M.

2022 EBITDA Forecast
$0.04B
2023 EBITDA Forecast
$0.04B
2024 EBITDA Forecast
$0.04B
2025 EBITDA Forecast
$0.04B
2026 EBITDA Forecast
$0.04B
2027 EBITDA Forecast
$0.04B
2028 EBITDA Forecast
$0.04B
2029 EBITDA Forecast
$0.04B
2030 EBITDA Forecast
$0.04B

Catalyst Pharmaceuticals EBIT Forecast for 2023 - 2025 - 2030

In the last two years, Catalyst Pharmaceuticals's EBIT has grown, moving from $31.82M to $52.39M – an increase of 64.64%. According to the 0 analysts polled, in the next year, Catalyst Pharmaceuticals's EBIT will fall by 21.76%, reaching $40.99M. By 2030, professionals believe that Catalyst Pharmaceuticals's EBIT will have decreased by 18.57%, falling to $42.66M.

2022 EBIT Forecast
$0.04B
2023 EBIT Forecast
$0.04B
2024 EBIT Forecast
$0.04B
2025 EBIT Forecast
$0.04B
2026 EBIT Forecast
$0.04B
2027 EBIT Forecast
$0.04B
2028 EBIT Forecast
$0.04B
2029 EBIT Forecast
$0.04B
2030 EBIT Forecast
$0.04B

Catalyst Pharmaceuticals EPS Price Prediction Forecast for 2023 - 2025 - 2030

In the last two years, Catalyst Pharmaceuticals's EPS has grown by 23.33%, rising from $0.30 to $0.37. In the following year, 0 experts forecast that Catalyst Pharmaceuticals's EPS will decrease by 2.93%, to $0.36. In 2030, professionals predict that Catalyst Pharmaceuticals's EPS will decrease by 2.48%, to $0.36.

2022 EPS Forecast
$0.36
2023 EPS Forecast
$0.34
2024 EPS Forecast
$0.36
2025 EPS Forecast
$0.36
2026 EPS Forecast
$0.36
2027 EPS Forecast
$0.36
2028 EPS Forecast
$0.36
2029 EPS Forecast
$0.36
2030 EPS Forecast
$0.36